Analysts See $-0.26 EPS for Fate Therapeutics, Inc. (FATE)

February 15, 2018 - By Marguerite Chambers

 Analysts See $ 0.26 EPS for Fate Therapeutics, Inc. (FATE)
Investors sentiment increased to 1.79 in Q3 2017. Its up 0.36, from 1.43 in 2017Q2. It increased, as 3 investors sold Fate Therapeutics, Inc. shares while 16 reduced holdings. 17 funds opened positions while 17 raised stakes. 24.55 million shares or 4.67% less from 25.76 million shares in 2017Q2 were reported.
Tiaa Cref Management Limited Liability Co holds 102,021 shares or 0% of its portfolio. Blackrock Incorporated owns 1.66M shares. Retail Bank Of Montreal Can has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE). Community National Bank Na reported 0% stake. First Manhattan Com owns 1,250 shares. Guggenheim Limited Liability has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Geode Capital Management Ltd Liability Com has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Dimensional Fund Limited Partnership holds 23,500 shares. Vanguard Group Inc Inc stated it has 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Barclays Public Ltd Liability Company reported 2,683 shares stake. Wells Fargo & Commerce Mn owns 243,754 shares. Jacobs Levy Equity Mngmt holds 0% or 16,300 shares. Polaris Venture Co V Limited Liability Corporation holds 8.42% in Fate Therapeutics, Inc. (NASDAQ:FATE) or 2.47 million shares. The Massachusetts-based State Street has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Citigroup owns 70 shares.

Since October 13, 2017, it had 0 insider purchases, and 3 insider sales for $148,927 activity. Shoemaker Daniel D sold $51,203 worth of stock or 13,225 shares. The insider TAHL CINDY sold $31,124.

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $-0.26 EPS on March, 15.They anticipate $0.05 EPS change or 23.81 % from last quarter’s $-0.21 EPS. After having $-0.26 EPS previously, Fate Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.16% or $0.09 during the last trading session, reaching $8.08. About 145,524 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 166.12% since February 15, 2017 and is uptrending. It has outperformed by 149.42% the S&P500.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 9 analysts covering Fate Therapeutics (NASDAQ:FATE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 12 analyst reports since October 6, 2015 according to SRatingsIntel. The stock has “Buy” rating by BMO Capital Markets on Wednesday, November 1. On Thursday, October 12 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. On Thursday, September 22 the stock rating was initiated by Roth Capital with “Buy”. BMO Capital Markets initiated the stock with “Outperform” rating in Tuesday, April 12 report. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Buy” rating given on Friday, September 8 by Leerink Swann. On Tuesday, October 6 the stock rating was initiated by Raymond James with “Outperform”. TH Capital initiated the shares of FATE in report on Thursday, September 22 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, December 13. Wedbush maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Tuesday, November 8. Wedbush has “Outperform” rating and $7 target.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $412.06 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

Another recent and important Fate Therapeutics, Inc. (NASDAQ:FATE) news was published by which published an article titled: “Here’s Why Fate Therapeutics Rose as Much as 18% Today” on January 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.